Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 05 April 2026, providing investors with the latest insights into the company’s performance and outlook.

Oxygenta Pharmaceutical Ltd’s stock price declined sharply on 1 April 2026, hitting a new 52-week low of Rs.45.3. This marks a significant drop for the micro-cap pharmaceutical company, reflecting ongoing challenges in its financial and market performance amid a broader mixed market environment.

Oxygenta Pharmaceutical Ltd’s share price declined to a fresh 52-week low of ₹45.83 on 30 March 2026, marking a significant milestone in the stock’s ongoing downward trajectory. Despite an intraday high of ₹49.90, the stock closed sharply lower, reflecting persistent pressures within the Pharmaceuticals & Biotechnology sector and broader market weakness.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 12 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Oxygenta Pharmaceutical Ltd’s shares declined sharply to a new 52-week low of Rs.46 on 4 March 2026, marking a significant downturn amid a challenging year for the company. This latest low reflects ongoing pressures on the stock, which has underperformed the broader market and its sector over the past twelve months.

Oxygenta Pharmaceutical Ltd’s shares declined sharply to a new 52-week low of Rs.46 today, marking a significant downturn in the stock’s performance amid broader market fluctuations and company-specific concerns.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Oxygenta Pharmaceutical Ltd’s shares declined sharply to a new 52-week low of Rs.46.6 today, marking a significant downturn amid broader market weakness and company-specific headwinds. The stock’s performance continues to trail the sector and benchmark indices, reflecting ongoing concerns about its financial health and market positioning.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 06 February 2026, providing investors with the most recent insights into the company’s performance and outlook.

Oxygenta Pharmaceutical Limited, a micro-cap pharmaceutical company with a market capitalisation of ₹226.00 crores, reported a net loss of ₹4.84 crores for Q3 FY26 (October-December 2025), representing a marginal improvement of 1.83% quarter-on-quarter but a 23.16% deterioration year-on-year. The stock, trading at ₹60.00 as of February 5, 2026, declined 1.70% on the day, reflecting investor concerns about the company's persistent inability to achieve profitability despite robust top-line growth.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 26 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Oxygenta Pharmaceutical Ltd’s shares declined to a fresh 52-week low of Rs.51.31 on 21 Jan 2026, marking a significant downturn amid broader market weakness and company-specific headwinds. The stock has underperformed its sector and benchmark indices, reflecting ongoing concerns about its financial health and market positioning.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 04 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 24 December 2025, providing investors with the latest insights into its performance and outlook.